专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明公开

EP0722936A4 FUSED PYRIDAZINE COMPOUND 失效
标题翻译：简明哒嗪
公开(公告)号：EP0722936A4
公开(公告)日：1996-12-11
申请号：EP95927990
申请日：1995-08-08
申请人： EISAI CO LTD
发明人： WATANABE NOBUHISA , KABASAWA YASUHIRO , TAKASE YASUTAKA , OZAKI FUMIHIRO , ISHIBASHI KEIJI , MIYAZAKI KAZUKI , MATSUKURA MASAYUKI , SOUDA SHIGERU , MIYAKE KAZUTOSHI , ISHIHARA HIROKI , KODAMA KOHTARO , ADACHI HIDEYUKI
IPC分类号： C07D237/34 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D471/04 , C07D521/00 , C07D237/30 , A61K31/50 , C07D237/32
CPC分类号： C07D231/12 , C07D233/56 , C07D237/34 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D471/04
摘要： A fused pyridazine compound represented by general formula (I) and having the inhibitory effect against cyclic GMP-phosphodiesterase (cGMP-PDE), and a pharmacologically acceptable salt thereof. These compounds are useful as preventives and remedies for diseases against which the cGMP-PDE inhibitory effect is efficacious, such as ischemic heart diseases including angina pectoris, myocardial infarct, and chronic and acute cardiac failures, pulmonary hypertension, arteriosclerosis, and bronchial asthma.

12. 发明公开

EP1439175A4 PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF 有权
标题翻译： PYRIMIDINVERBINDUNG UND DIESE ENTHALTENDE MEDIZINISCHE ZUSAMMENSETZUNG
公开(公告)号：EP1439175A4
公开(公告)日：2004-12-29
申请号：EP02802050
申请日：2002-10-22
申请人： EISAI CO LTD
发明人： HARADA HITOSHI , ASANO OSAMU , UEDA MASATO , MIYAZAWA SHUHEI , KOTAKE YOSHIHIKO , KABASAWA YASUHIRO , YASUDA MASAHIRO , YASUDA NOBUYUKI , IIDA DAISUKE , NAGAKAWA JUNICHI , HIROTA KAZUO , NAKAGAWA MAKOTO
IPC分类号： A61K31/506 , A61P1/00 , A61P1/10 , A61P3/04 , A61P3/10 , A61P9/12 , A61P11/06 , A61P13/02 , A61P19/10 , A61P25/16 , A61P25/28 , A61P43/00 , C07D401/04 , C07D405/14 , C07D409/14
CPC分类号： C07D405/14 , A61K31/506 , C07D401/04 , C07D409/14
摘要： A novel pyrimidine compound having an excellent antagonistic activity against adenosine receptors (A1, A2A, and A2B receptors). Specifically, it is a compound represented by the following formula, a salt of the compound, or a solvate of either. (I) In the formula, R1 and R2 are the same or different and each represents hydrogen, optionally substituted C1-6 alkyl, etc.; R3 represents hydrogen, halogeno, etc.; R4 represents an optionally substituted C6-14 aromatic hydrocarbon ring group, optionally substituted 5- to 14-membered nonaromatic heterocyclic group having at least one unsaturated bond, etc.; and R5 represents an optionally substituted C6-14 aromatic hydrocarbon ring group or optionally substituted 5- to 14-membered aromatic heterocyclic group.
摘要翻译：对腺苷受体（A1，A2A和A2B受体）具有优异拮抗活性的新型嘧啶化合物。具体地说，它是由下式表示的化合物，该化合物的盐或任一种的溶剂化物。（I）式中，R 1和R 2相同或不同，表示氢原子，可以具有取代基的C 1-6烷基等。 R3代表氢，卤代等; R4表示任选取代的C6-14芳族烃环基团，具有至少一个不饱和键的任选取代的5-14元非芳族杂环基团等; 并且R 5表示任选取代的C 6-14芳族烃环基团或任选取代的5至14元芳族杂环基团。

13. 发明公开

EP0920868A4 REMEDY FOR ERECTION FAILURE COMPRISING FUSED PYRIDAZINE COMPOUND 失效
标题翻译：稠哒嗪化合物含固化EREKTIONSSTOERUNGEN
公开(公告)号：EP0920868A4
公开(公告)日：2004-05-26
申请号：EP97934748
申请日：1997-08-08
申请人： EISAI CO LTD
发明人： WATANABE NOBUHISA , KABASAWA YASUHIRO , ABE SHINYA , SHIBAZAKI MAYU , ISHIHARA HIROKI , KODAMA KOHTAROU , ADACHI HIDEYUKI
IPC分类号： C07D237/34 , A61K31/50
CPC分类号： C07D237/34
摘要： A remedy for erection failure containing as the active ingredient a fused pyridazine compound represented by general formula (I) or a pharmacologically acceptable salts thereof, wherein ring C represents an aromatic five- or six-membered ring which may bear heteroatom(s); n represents an integer of 1 to 4; R1 represents hydrogen, halogeno, cyano, etc.; A represents hydrogen, halogeno, optionally substituted amino, etc.; X represents -N= etc.; and Y represents -CO-, optionally substituted amino, etc.

14. 发明专利

NZ532373A Pyrimidine compound and medicinal composition thereof 未知
公开(公告)号：NZ532373A
公开(公告)日：2007-02-23
申请号：NZ53237302
申请日：2002-10-22
申请人： EISAI CO LTD
发明人： HARADA HITOSHI , ASANO OSAMU , UEDA MASATO , MIYAZAWA SHUHEI , KOTAKE YOSHIHIKO , KABASAWA YASUHIRO , YASUDA MASAHIRO , YASUDA NOBUYUKI , IIDA DAISUKE , NAGAKAWA JUNICHI , HIROTA KAZUO , NAKAGAWA MAKOTO
IPC分类号： A61K31/506 , A61P1/00 , A61P1/10 , A61P3/04 , A61P3/10 , A61P9/12 , A61P11/06 , A61P13/02 , A61P19/10 , A61P25/16 , A61P25/28 , A61P43/00 , C07D401/04 , C07D405/14 , C07D409/14
摘要： Disclosed are pyrimidine derivatives of formula (I) wherein: R1 and R2 are H; R3 is H, amino, halogen, cyano, alkyl, alkenyl, alkynyl, aromatic hydrocarbon cyclic group, aromatic heterocyclic group, N, O or S; R4 is a group of formula (IV) wherein R8 is as defined; and R5 represents an aromatic hydrocarbon cyclic group. Also disclosed is the use of the above compounds as adenosine A2A and A2B receptor antagonists useful in the treatment of Parkinson's disease, depression, constipation, diabetes, glucose intolerance, Alzheimer's disease, inflammatory bowel disease and Crohn's disease amongst other uses.

15. 发明专利

DE69533057T2 未知
公开(公告)号：DE69533057T2
公开(公告)日：2005-06-16
申请号：DE69533057
申请日：1995-08-08
申请人： EISAI CO LTD
发明人： WATANABE NOBUHISA , KABASAWA YASUHIRO , TAKASE YASUTAKA , OZAKI FUMIHIRO , ISHIBASHI KEIJI , MIYAZAKI KAZUKI , MATSUKURA MASAYUKI , SOUDA SHIGERU , MIYAKE KAZUTOSHI , ISHIHARA HIROKI , KODAMA KOHTARO , ADACHI HIDEYUKI
IPC分类号： C07D237/34 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D471/04 , C07D521/00 , C07D237/30 , C07D237/32 , A61K31/50
摘要： A fused pyridazine compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof which exhibits an inhibitory activity against cyclic GMP phosphodiesterase (hereinafter referred to as "cGMP-PDE"). The compounds are useful as preventive and therapeutic agents for diseases for which a cGMP-PDE inhibiting action is efficacious, for example, ischemic heart diseases such as angina pectoris, myocardial infarct and chronic and acute cardiac failure, pulmonary hypertension, arteriosclerosis and bronchial asthma.

16. 发明专利

PL370274A1 PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF 未知
公开(公告)号：PL370274A1
公开(公告)日：2005-05-16
申请号：PL37027402
申请日：2002-10-22
申请人： EISAI CO LTD
发明人： HARADA HITOSHI , ASANO OSAMU , UEDA MASATO , MIYAZAWA SHUHEI , KOTAKE YOSHIHIKO , KABASAWA YASUHIRO , YASUDA MASAHIRO , YASUDA NOBUYKI , IIDA DAISUKE , NAKAGAWA JUNICHI , HIROTA KAZUO , NAKAGAWA MAKOTO
IPC分类号： A61K31/506 , A61P1/00 , A61P1/10 , A61P3/04 , A61P3/10 , A61P9/12 , A61P11/06 , A61P13/02 , A61P19/10 , A61P25/16 , A61P25/28 , A61P43/00 , C07D401/04 , C07D405/14 , C07D409/14
摘要： The present invention provides a novel pyrimidine compound having an excellent adenosine receptor (A 1 , A 2A , A 2B receptor) antagonistic action. More specifically, it provides a compound represented by the following formula, a salt thereof or a solvate of them. In the formula, R 1 and R 2 are the same as or different from each other and each represents a hydrogen atom, an alkyl group having one to sixcarbon atoms which maybe substituted, an alkenyl group having two to six carbon atoms which may be substituted, an alkynyl group having two to six carbon atoms which may be substituted, a cycloalkyl group having three to eight carbon atoms which may be substituted, a cycloalkenyl group having three to eight carbon atoms which may be substituted, a 5 to 14-membered non-aromatic heterocyclic group which may be substituted, an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted, a 5 to 14-membered aromatic heterocyclic group which may be substituted, an acyl group having one to six carbon atoms which may be substituted or an alkylsulfonyl group having one to six carbon atoms which may be substituted; R 3 represents a hydrogen atom, a halogen atom, a cyano group, an alkyl group having one to six carbon atoms which may be substituted, an alkenyl group having two to six carbon atoms which may be substituted, an alkynyl group having two to six carbon atoms which may be substituted, an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted, a 5 to 14-membered aromatic heterocyclic group which may be substituted, a nitrogen atom which may be substituted, an oxygen atom which may be substituted or a sulfur atom which may be substituted; R 4 represents a 4-pyridyl group which may have one or two substituents; and R 5 represents an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted or a 5 to 14-membered aromatic heterocyclic group which may be substituted.

17. 发明专利

AU722710B2 Remedy for erection failure comprising fused pyridazine compound 未知
公开(公告)号：AU722710B2
公开(公告)日：2000-08-10
申请号：AU3784897
申请日：1997-08-08
申请人： EISAI CO LTD
发明人： WATANABE NOBUHISA , KABASAWA YASUHIRO , ABE SHINYA , SHIBAZAKI MAYU , ISHIHARA HIROKI , KODAMA KOHTAROU , ADACHI HIDEYUKI
IPC分类号： C07D237/34 , A61K31/50 , C07D237/30
摘要： The present invnetion provides a remedy for erectile dysfunction. The active ingredient thereof is a fused pyridazine compound represented by the following formula (I) or a pharmacologically acceptable salt thereof: (wherein the ring C represents a 5 or 6 membered ring optionally having hetero atom(s); n is an integer of from 1 to 4; R represents a hydrogen, a halogen, a cyano, etc.; A represents a hydrogen, a halogen, an optionally substituted amino, etc.; X represents a group represented by the formula -N=, etc.; and Y represents the formula -CO-, an optionally substituted amino, etc).

18. 发明专利

NO990805D0 未知
公开(公告)号：NO990805D0
公开(公告)日：1999-02-19
申请号：NO990805
申请日：1999-02-19
申请人： EISAI CO LTD
发明人： WATANABE NOBUHISA , KABASAWA YASUHIRO , ABE SHINYA , SHIBAZAKI MAYU , ISHIHARA HIROKI , KODAMA KOHTAROU , ADACHI HIDEYUKI
IPC分类号： C07D237/34 , A61K
摘要： The present invnetion provides a remedy for erectile dysfunction. The active ingredient thereof is a fused pyridazine compound represented by the following formula (I) or a pharmacologically acceptable salt thereof: (wherein the ring C represents a 5 or 6 membered ring optionally having hetero atom(s); n is an integer of from 1 to 4; R represents a hydrogen, a halogen, a cyano, etc.; A represents a hydrogen, a halogen, an optionally substituted amino, etc.; X represents a group represented by the formula -N=, etc.; and Y represents the formula -CO-, an optionally substituted amino, etc).

19. 发明专利

AT166046T 未知
公开(公告)号：AT166046T
公开(公告)日：1998-05-15
申请号：AT94114467
申请日：1994-09-14
申请人： EISAI CO LTD
发明人： KABASAWA YASUHIRO , OZAKI FUMIHIRO , ISHIBASHI KEIJI , HASEGAWA TAKASHI , OINUMA HITOSHI , SHIRATO MANABU , MORIYA KATSUHIRO , OGAWA TOSHIAKI , KATAYAMA SATOSHI , SOUDA SHIGERU
IPC分类号： C07C13/18 , A61K31/015 , A61K31/13 , A61P21/00 , C07C327/46 , C07D471/04 , C07D521/00 , C07C235/00 , C07C311/19 , A61K31/165 , A61K31/44
摘要： To provide a novel cyclohexane derivative, a cyclohexane derivative is defined by the formula (I) or a pharmacologically acceptable salt thereof: (wherein R and R may be the same or different from each other and each represents hydrogen or lower alkyl; R represents optionally substituted aryl or optionally substituted heteroaryl; X represents oxygen or sulfur; and Y represents a group represented by the formula: or the like). The compound of the present invention is useful as a preventive and therapeutic agent for diseases against which a potassium channel opening action is efficacious.

20. 发明专利

AU3191995A Fused pyridazine compound 未知
公开(公告)号：AU3191995A
公开(公告)日：1996-03-07
申请号：AU3191995
申请日：1995-08-08
申请人： EISAI CO LTD
发明人： WATANABE NOBUHISA , KABASAWA YASUHIRO , TAKASE YASUTAKA , OZAKI FUMIHIRO , ISHIBASHI KEIJI , MIYAZAKI KAZUKI , MATSUKURA MASAYUKI , SOUDA SHIGERU , MIYAKE KAZUTOSHI , ISHIHARA HIROKI , KODAMA KOHTARO , ADACHI HIDEYUKI
IPC分类号： C07D237/34 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D471/04 , C07D521/00 , C07D237/30 , C07D237/32 , A61K31/50
摘要： A fused pyridazine compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof which exhibits an inhibitory activity against cyclic GMP phosphodiesterase (hereinafter referred to as "cGMP-PDE"). The compounds are useful as preventive and therapeutic agents for diseases for which a cGMP-PDE inhibiting action is efficacious, for example, ischemic heart diseases such as angina pectoris, myocardial infarct and chronic and acute cardiac failure, pulmonary hypertension, arteriosclerosis and bronchial asthma.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式